ArticleObesity surgery2026
Revisional Metabolic and Bariatric Surgery Versus Semaglutide: Which Strategy Has Greater Efficacy for Recurrent Weigh Gain After Primary Bariatric Surgery?
Article in Obesity surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
- Erratum issued
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite metabolic and bariatric surgery (MBS) being the most effective treatment for obesity and its related comorbidities, a significant proportion of patients experience recurrent weight gain (RWG) after primary surgery. In this setting, management options include revisional bariatric surgery (RMBS) and pharmacologic therapy with glucagon-like peptide-1 receptor agonists such as semaglutide. However, comparative data evaluating the effectiveness of both options for the management of RWG after primary MBS remain limited.
objectivesThis study aimed to compare weight loss outcomes between patients receiving semaglutide and those undergoing revisional metabolic and bariatric surgery (RMBS) due to RWG.
methodsA retrospective cohort study was conducted in patients who underwent MBS between 2015 and 2020 and had RWG postoperatively. These patients were managed with semaglutide (Group A) or RMBS (Group B), including patients with previous sleeve gastrectomy that were converted to Roux-en-Y gastric bypass (RYGB) or patients with previous RYGB that underwent revision of the bypass. The primary outcomes were excess BMI loss (%EBMIL), excess weight loss (%EWL), and total weight loss (%TWL) at 2 years following the new intervention.
resultsA total of 250 patients were included, 120 patients in Group A and 130 in Group B. 90% (n = 225) of patients were female, with an average age of 41.3 ± 12 years. The mean body mass index (BMI) pre-intervention, at one year and two years follow-up, was 39.13 ± 8.53, 37.45 ± 8.95, and 40.36 ± 9.82 Kg/m2 for Group A and 41.14 ± 8.15, 34.01 ± 6.69, and 34.93 ± 8.51 Kg/m2 for Group B. Statistically significant differences in BMI were noted between the groups at one year (p = 0.001) and two years (p = 0.011). At two years, %EBMIL, %EWL, and %TWL were 8.32%, 6.1%, and 2.8% for Group A, and 36%, 45.76%, and 17.47% for Group B (p = 0.045, p = 0.006, and p < 0.001 respectively).
conclusionIn this specific cohort of patients with obesity who underwent a primary bariatric procedure and experienced RWG, RMBS was associated with greater weight-loss outcomes compared to semaglutide at 2-year follow-up. The lack of reported safety and complication data for RMBS limits definitive comparisons between management strategies.
Indexed as
Identifiers
41906069What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.